LBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

LB PHARMACEUTICALS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$38.81+2.07 (+5.63%)

Close on Oct 19, 2026

Market cap: $1.17B
P/E (TTM): –
Dividend yield: –

LB PHARMACEUTICALS INC balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31
Cash & Equivalents	283	321	250	270	–	–	23	–	–	–	–
Short-Term Investments	45	45	45	45	–	–	5.02	–	–	–	–
Cash & Short-Term Investments	325	365	295	315	–	–	25	–	–	–	–
Prepaid Expenses & Other	28	23	13	1.92	–	–	0.88	–	–	–	–
Total Current Assets	355	389	308	316	–	–	29	–	–	–	–
Property, Plant & Equipment	2.20	1.53	1.58	1.64	–	–	1.86	–	–	–	–
Gross Property, Plant & Equipment	2.80	2.03	2.00	1.97	–	–	1.96	–	–	–	–
Accumulated Depreciation	-0.60	-0.50	-0.42	-0.34	–	–	-0.10	–	–	–	–
Operating Lease Right-of-Use Assets	3.41	2.10	2.15	2.20	–	–	2.30	–	–	–	–
Total Assets	362	393	313	321	–	–	34	–	–	–	–
Accounts Payable	3.49	7.12	2.13	2.59	–	–	2.32	–	–	–	–
Accrued Expenses	19	3.06	4.59	3.33	–	–	5.30	–	–	–	–
Current Portion of Leases	0.84	0.73	0.73	0.73	–	–	0.49	–	–	–	–
Total Current Liabilities	24	11	7.44	6.65	–	–	8.11	–	–	–	–
Long-Term Leases	4.37	2.74	2.84	2.94	–	–	3.22	–	–	–	–
Operating Lease Liabilities	5.22	3.47	3.57	3.67	–	–	3.70	–	–	–	–
Total Liabilities	29	15	12	11	–	–	14	–	–	–	–
Common Stock	0.00	0.00	0.00	114	–	–	0.00	–	–	–	–
Additional Paid-In Capital	532	527	431	428	–	–	9.66	–	–	–	–
Retained Earnings	-200	-149	-130	-118	–	–	-104	–	–	–	–
Comprehensive Income & Other	0.19	0.21	0.17	-0.05	–	–	0.11	–	–	–	–
Shareholders' Equity	332	379	301	310	-104	-99	-95	-91	-77	-50	-34
Total Equity	332	379	301	310	-104	-99	-95	-91	-77	-50	-34
Total Liabilities & Equity	362	393	313	321	–	–	34	–	–	–	–
Shares Outstanding(shares)	29	29	25	25	–	–	0.25	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -24.4%

Financial strength

Current ratio: 15.08
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1201.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.52
Dividend yield: –